Related Experiment Video
Updated: Aug 22, 2025
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations
Iris K van Alderwerelt van Rosenburgh1,2,3, David M Lu1,2,3, Michael J Grant3,4
1Department of Pharmacology, Yale University School of Medicine, New Haven, CT, 06520, USA.
Abstract:
Tyrosine kinase inhibitors (TKIs) are used to treat non-small cell lung cancers (NSCLC) driven by epidermal growth factor receptor (EGFR) mutations in the tyrosine kinase domain (TKD). TKI responses vary across tumors driven by the heterogeneous group of exon 19 deletions and mutations, but the molecular basis for these differences is not understood. Using purified TKDs, we compared kinetic properties of several exon 19 variants. Although unaltered for the second generation TKI afatinib, sensitivity varied significantly for both the first and third generation TKIs erlotinib and osimertinib. The most sensitive variants showed reduced ATP-binding affinity, whereas those associated with primary resistance retained wild type ATP-binding characteristics (and low KM, ATP). Through crystallographic and hydrogen-deuterium exchange mass spectrometry (HDX-MS) studies, we identify possible origins for the altered ATP-binding affinity underlying TKI sensitivity and resistance, and propose a basis for classifying uncommon exon 19 variants that may have predictive clinical value.
Insights
Tyrosine kinase inhibitors (TKIs) effectiveness varies in non-small cell lung cancer (NSCLC) due to EGFR exon 19 mutations. Altered ATP-binding affinity explains differential TKI sensitivity and resistance, aiding variant classification.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Tyrosine kinase inhibitors (TKIs) target EGFR mutations in non-small cell lung cancer (NSCLC).
- Exon 19 deletions and mutations in EGFR exhibit heterogeneous responses to TKIs.
- The molecular basis for varying TKI sensitivity in NSCLC remains unclear.
Purpose of the Study:
- To investigate the kinetic properties of EGFR exon 19 variants.
- To understand the molecular mechanisms underlying differential TKI sensitivity and resistance.
- To establish a basis for classifying uncommon EGFR exon 19 variants for clinical prediction.
Main Methods:
- Purified EGFR tyrosine kinase domains (TKDs) were used for kinetic analysis.
- Comparison of TKI sensitivity across different exon 19 variants.
- Crystallography and hydrogen-deuterium exchange mass spectrometry (HDX-MS) were employed.
Main Results:
- TKI sensitivity varied significantly for first-generation (erlotinib) and third-generation (osimertinib) TKIs, but not for second-generation (afatinib).
- EGFR variants with reduced ATP-binding affinity showed increased sensitivity to certain TKIs.
- Variants with wild-type ATP-binding characteristics (low KM, ATP) were associated with primary resistance.
Conclusions:
- Altered ATP-binding affinity is a key determinant of TKI sensitivity and resistance in EGFR exon 19 mutated NSCLC.
- Structural and kinetic insights explain differential responses to various TKIs.
- A classification system for uncommon exon 19 variants may offer predictive clinical value for NSCLC treatment.
More Related Videos
10:57Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay
Published on: August 14, 2018
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
